Timing of Trastuzumab administration when given along with chemotherapy in an adjuvant setting, is gaining more clarity. Updated information presented at the 2009 San Antonio Breast Cancer Symposium suggests that, as was administered in group C of the N9831 trial, Trastuzumab started concurrently with taxane resulted in a better outcome, with improvement in Disease Free Survival compared to sequentially administering Trastuzumab following completion of taxane chemotherapy. This should clearly be more appealing to patients, as the duration of adjuvant parenteral therapy would be shortened by approximately 3 months in addition to the decrease in the risk of disease recurrence.
Other Pages – Bottom Ad
Advertisement
Subscribe
